In situ and operando characterisation techniques for solid oxide electrochemical cells: recent advances

Recent Advances in Electrochemical Immunosensors

Immunosensors have experienced a very significant growth in recent years, driven by the need for fast, sensitive, portable and easy-to-use devices to detect biomarkers for clinical diagnosis or to monitor organic pollutants in natural or industrial environments. Advances in the field of signal amplification using enzymatic reactions, nanomaterials such as carbon nanotubes, graphene and graphene...

Operando X-ray Investigation of Electrode/Electrolyte Interfaces in Model Solid Oxide Fuel Cells

We employed operando anomalous surface X-ray diffraction to investigate the buried interface between the cathode and the electrolyte of a model solid oxide fuel cell with atomic resolution. The cell was studied under different oxygen pressures at elevated temperatures and polarizations by external potential control. Making use of anomalous X-ray diffraction effects at the Y and Zr K-edges allow...

In Situ X-ray and Electrochemical Studies of Solid Oxide Fuel Cell / Electrolyzer Oxygen Electrodes

The governing reaction mechanisms, and the electrode material compositions and structures, that controls the efficiency of the solid oxide fuel cells (SOFC) and solid oxide electrolysis cells (SOEC) need to be identified and well-understood for significant technological improvements. Our study on the oxygen electrodes focuses on specifically the effect of electrode crystal structure and morphol...

Recent Advances in EMG Pattern Recognition for Prosthetic Control

Recent Advances in Hemophilia Gene Therapy

Heterogeneous loss of function mutations at F8 and F9 genes causes X-linked recessive bleeding disorders, hemophilia A (HA) and hemophilia B (HB), respectively. HA is clinically indistinguishable from HB and accounts for more than 80% of hemophilia cases; the former affects 1/5000 and the latter 1/25000 male births worldwide. In Iran, it is estimated that around 4300 HA and 900 HB patients are ...